Is the price fair?
What ASND's price assumes
Ascendis Pharma A/S did not earn a profit over the last twelve months, so it has no trailing P/E and the price is read against sales instead: 18.7× revenue.
18.7
Price / sales · no P/E: the last twelve months did not end in a profit
- EV / sales
- 19.3
EV / sales
Details›
- EV / EBIToperating margin −19%: the multiple describes the denominator
- not meaningful
- EV / sales2025-Q3
- 19.3
- Market capitalisation
- $15.1B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Biotechnology
Ranks #59 of 145 by Smart Score